Insuficiencia Cardiaca

Insuf Card 2016; 11 (3): 115-121

Pulmonary arterial hypertension in adult congenital heart disease

Impact and outcome

Data from the GUTI-GUCH Registry

Claudio Gabriel Morós, Marisa Pacheco Otero, Gianina Faliva, María del Carmen Rubio, Mariana López Daneri, Isabel Torres, Inés Abella, Álvaro Sosa Liprandi, Liliana Noemí Nicolosi, María Grippo

Introduction

Adult congenital heart disease (ACHD) is one of the fastest growing cardiology subgroups in recent years due to early diagnosis and advances in surgical and endovascular treatment. It is calculated that 85-95% of patients with congenital heart disease will reach adulthood. The survival of these patients create complications and sequelae that contribute to higher  rates of hospitalization and new surgeries, among other procedures.

It is estimated that 5 to 10% of patients with ACHD will develop pulmonary hypertension (PH) in its progression, making it one of the most common causes of pulmonary arterial hypertension (PAH), after connective tissues diseases. Its occurrence is related to a worse prognosis.

The objective of this present study was to analyze the epidemiological characteristics, clinical and pharmacological treatment in patients with PAH and their impact on survival.

Vasilya Nizamova

SPA 4003

Prof. Esther Allen

INSUFICIENCIA CARDIACA

Insuf Card 2016;11 (3): 115-121

Pulmonary Arterial Hypertension in Adult Congenital Heart Disease

Impact and Outcome

Data from the GUTI-GUCH Registry

Claudio Gabriel Morós, Marisa Pacheco Otero, Gianina Faliva, María del Carmen Rubio, Mariana López Daneri, Isabel Torres, Inés Abella, Álvaro Sosa Liprandi, Liliana Noemí Nicolosi, María Grippo

Introduction

Adult congenital heart disease (ACHD) is one of the fastest-growing cardiology subgroups in recent years, due to early diagnosis and advances in surgical and endovascular treatment. It is estimated that 85-90% of patients with congenital heart disease reach adult age. The survival of these patients generates complications and sequelae that contribute to higher rates of hospitalizations and new surgeries, among other procedures.

During its progression, an estimated 5 to 10% of patients with ACHD will develop pulmonary hypertension (PH), which in reality is the most frequent cause of pulmonary arterial hypertension (PAH) after connective tissue disease. The occurrence of PAH is related to a worse prognosis for the patient.

The objective of the present study was to analyze epidemiological, clinical and pharmacotherapy characteristics of patients with PAH and their impact on survival.

HEART FAILURE

Insuf Card 2016; 11 (3): 115-121

Pulmonary Arterial Hypertension in adults with congenital heart disease

Impact and result

Registry data GUTI-GUCH

Claudio Gabriel Moros, Marisa Pacheco Otero, Gianina Faliva, Maria del Carmen Rubio, Mariana Lopez Daneri, Isabel Torres, Ines Aballa, Alvaro Sosa Lipradi, Liliana Noemi Nicolosi, Maria Grippo

Introduction

Adult Congenital Heart Disease (ACHD) is one of the fastest growing cardiology subgroups in recent years, due to early diagnosis and advances in surgical and endovascular treatment. 85-90% of patients with congenital heart disease will get to the adulthood. The survival of these patients generates complications and sequela as result of hospitalizations rate and new surgeries, and others procedures.

From 5 to 10% estimated patients with ACHD develop Pulmonary Hypertension (PH) on its progression, being actually the most frequent cause of Pulmonary Arterial Hypertension (PAH) after the connective tissue disease. Its appearance relate to a worse prognostic of the patient.

The objective of the present study is to analyze the epidemiology characteristics, clinical and pharmacological treatment of patients with PAH and its survival impact.

INSUFICIENCIA CARDIACA

Insuf Card 2016;11 (3): 115-121

Pulmonary arterial hypertension in adult congenital heart disease  

Impact and results

Data from the GUTI-GUCH Registry

Claudio Gabriel Morós, Marisa Pacheco Otero, Gianina Faliva, María del Carmen Rubio,  Mariana López Daneri, Isabel Torres, Inés Abella, Álvaro Sosa Liprandi, Liliana Noemí Nicolosi, María Grippo

Adult congenital heart disease (ACHD) is one of the fastest growing cardiology subgroups in recent years, due to early diagnosis and advances in surgical and endovascular treatment. It is estimated that 85-90% of patients with congenital heart disease will reach adulthood. The survival of these patients generates complications, and consequences that contribute to a higher rates of new surgeries, hospitalization, among other procedures.

It is estimated that 5 to 10% of patients with ACHD develop pulmonary hypertension (PH) in its evolution, making it currently the most frequent cause of pulmonary arterial hypertension (PAH) after connective tissue diseases. Its occurrence is related with the worse patient prognosis.

The objective of the study was to analyze the epidemiological, clinical characteristics, and pharmacological treatment of patients with PAH and their impact on survival.

Introduction

Adult congenital heart disease (ACHD) is one of the fastest growing cardiology subgroups in recent years due to early diagnosis and advances in surgical and endovascular treatment. It’s calculated that 85-90% of patients with congenital heart disease will reach adulthood. The survival rate of these patients results in complications and sequelae that redound in a greater rate of hospitalization and new surgeries, among other procedures.

It is estimated that 5-10% of patients with ACHD develops Pulmonary hypertension (PH) through its progression, and currently being the most frequent cause for Pulmonary arterial hypertension (PAH), after connective tissue diseases. Its appearance is linked to a worst prognosis.

The objective of the present study is to analyze the epidemiological characteristics, clinical and pharmacological treatments in patients with PAH and its impact with PAH and its impact on the survival rate.

INSUFICIENCIA CARDIACA

Received: 06/25/2016

Accepted: 08/15/2016

Insuf Card 2016; 11 (3): 115-121                

Pulmonary arterial hypertension in adult congenital heart disease

Impact and outcome Data from the GUTI-GUCH Registry

Claudio Gabriel Morós, Marisa Pacheco Otero, Gianina Faliva, María del Carmen Rubio,  Mariana López Daneri, Isabel Torres, Inés Abella, Álvaro Sosa Liprandi, Liliana Noemí  Nicolosi, María Grippo

Introduction

Adult congenital heart disease (ACHD) is one of the fastest-growing cardiology subgroups in recent years, due to early diagnosis and advances in surgical and endovascular treatment. It is estimated that 85-90% of patients with congenital heart disease survive until adulthood. The survival of these patients generates complications and sequelae that results in higher rates of hospitalizations and new surgeries, among other procedures.

It is estimated that 5 to 10% of patients with ACHD will develop pulmonary hypertension (PH) in its progression, which is currently the most frequent cause of arterial pulmonary hypertension (APH) after connective tissue diseases. Its appearance is related to a worse prognosis for the patient.

The objective of the present study was to analyze the epidemiological characteristics, clinical and pharmacological treatments in patients with APH and their impact on survival.

INSUFICIENCIA CARDIACA

Insuf Card 2016;11 (3): 115-121

­­­­­­­­­­­­­­­___________________________________________________________________

Pulmonary arterial hypertension in adult congenital heart disease

Impact and outcome

Data from the GUTI-GUCH Registry

Claudio Gabriel Morós, Marisa Pacheco Otero, Gianina Faliva, María del Carmen Rubio,

Mariana López Daneri, Isabel Torres, Inés Abella, Álvaro Sosa Liprandi,

Liliana Noemí Nicolosi, María Grippo

Adult congenital heart disease (ACHD) is one of the fastest growing subgroups in recent years in cardiology due to early diagnosis and progression of surgical and endovascular treatments. It is estimated that 85-90% of patients with congenital heart disease will reach adulthood. The survival of these patients generates complications and sequelae that result in a higher rate of hospitalizations and new surgeries, among other procedures.

It is estimated that 5-10% of patients with ACHD will develop pulmonary hypertension (PH) in their evolution, currently being the most frequent cause of pulmonary arterial hypertension (PAH) after connective tissue diseases. Its occurrence is related with a worse prognosis for the patient.

The objective of the present study was to analyze the epidemiological characteristics, clinical and pharmacological treatment in patients with PAH and their impact on survival.

Vanesa Parra Henao

Insuficiencia Cardiaca

Pulmonary arterial hypertension in adult congenital heart disease

Impact and Outcome

Data from GUTI-GUCH Registry

Claudio Gabriel Morós, Marisa Pacheco Otero, Gianina Faliva, María del Carmen Rubio, Mariana López Daneri, Isabel Torres, Inés Abella, Álvaro Sosa Liprandi, Liliana Noemí Nicolosi, María Grippo

Introduction

Adult Congenital Heart Disease (ACHD) is one of the fastest-growing cardiology subgroups in recent years within cardiology due to early detection as well as advancements in surgical and endovascular treatments. It is estimated that 85-90% of patients with congenital heart disease live to adulthood. The survival of these individuals creates complications and sequels that result in a higher rate of hospitalization and surgery, among other procedures.

It is estimated that 5% to 10% of patients with ACHD develop pulmonary hypertension (PH) as ACHD evolves, which is currently the most frequent cause of pulmonary arterial hypertension (PAH) after connective tissue diseases. Its appearance is related to worst prognosis in patients.

The objective of the presented research was to analyze the epidemiological and clinical characteristics, as well as pharmaceutical treatment of patients with PAH and its impact on survival.

INSUFICIENCIA CARDIACA

Received: 06/25/2016
Accepted: 08/15/2016

Insuf Card 2016; 11 (3): 115-121       Available at: http://www.insufcienciacardiaca.org/

Pulmonary arterial hypertension in adult congenital heart disease
Impact and outcome Data from the GUTI-GUCH Registry

Claudio Gabriel Morós, Marisa Pacheco Otero, Gianina Faliva, María del Carmen Rubio,  Mariana López Daneri, Isabel Torres, Inés Abella, Álvaro Sosa Liprandi, Liliana Noemí  Nicolosi, María Grippo

Introduction
Adult congenital heart disease (ACHD) is one of the fastest growing  cardiology subgroups  in recent years, due to early diagnosis and advances in surgical and endovascular treatments. It is estimated that 85-90% of patients with congenital heart disease will reach adulthood. The survival of these patients generates complications and sequelae that lead to higher hospitalization rates and new surgeries, among other procedures.
During its progression, it is estimated that 5 to 10% of patients with ACHD will develop pulmonary hypertension (PH), presently being the prominent cause of pulmonary arterial hypertension (PAH), after connective tissue diseases. Its emergence is linked to a worse prognosis for the patient.
The objective of the present study was to analyze the characteristics of epidemiological, clinical, and pharmacological treatment in patients with PAH and its impact on survival.

INSUFICIENCIA CARDIACA

Insuf Card 2016,11 (3): 115-121

Pulmonary arterial hypertension in adult congenital heart disease

Impact and outcome

Data from the GUTI-GUCH Registry

Claudio Gabriel Morós, Marisa Pacheco Otero, Gianina Faliya, María  del Carmen Rubio, Mariana López Daneri, Isabel Abella, Álvaro Sosa Liprandi, Liliana Noemí Nicolosi, María Grippo

Introduction

The adult congenital heart disease (ACHD) is one of the fastest-growing cardiology subgroups in recent years, due to early diagnosis and advances in surgical and endovascular treatment. It’s estimated that the 85-95% of patients with congenital heart disease will reach adulthood. The survival of these patients generates complications and sequelae that results in a greater number of hospitalizations and new surgeries, among other procedures.

It is estimated that between 5 and 10% of the patients with ACHD will develop pulmonary hypertension (PH) during their evolution, being nowadays the most frequent cause of pulmonary arterial hypertension (PAH) after the connective tissue diseases. Its presence it is related with the worst patient’s prognosis.

The present study’s objective was to analyze the epidemiological characteristics as well as clinical and pharmacological treatments on patients with PAH and the impact on the survival rate.